Pyrazolo[1,5-α]Pyridine RET Inhibitors With Reduced VEGFR2 Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multi-target kinase inhibitors for RET kinases, such as Cabozantinib, Vandetanib, and Lenvatini, exhibit nonspecific inhibitory effects on RET and VEGFR2, leading to off-target toxicity and unsatisfactory efficacy due to kinase domain homologies.
Innovation Solution
Development of a pyrazolo[1,5-α]pyridine derivative with specific inhibitory activity against RET kinase, offering high selectivity and efficacy while minimizing off-target effects on VEGFR2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multi-target kinase inhibitors (Cabozantinib, Vandetanib, Lenvatini) are used to inhibit RET kinase, then broad kinase inhibition is achieved, but off-target toxicity increases due to inhibition of VEGFR2 and other kinases
Solution Approach 1:
The patent extracts and isolates the specific inhibitory action against RET kinase from the multi-target inhibition profile. By designing compounds that selectively target RET kinase through specific molecular interactions (binding to the ATP-binding pocket and forming hydrogen bonds with key residues), the invention separates the desired RET inhibition from unwanted off-target effects on VEGFR2 and other kinases, thereby reducing off-target toxicity while maintaining broad therapeutic applicability.
Solution Approach 2:
The patent applies local quality by optimizing specific molecular features and substituent patterns in the pyrazolo[1,5-a]pyridine core structure to enhance selectivity for RET kinase. By carefully selecting substituents at specific positions (R1, R2, R3, R4 groups) that form favorable interactions with unique residues in the RET kinase binding pocket, the compound achieves localized high-affinity binding to RET while having minimal interaction with VEGFR2 and other kinases, thus resolving the contradiction between versatility and toxicity.
2Adaptability or versatility
If multi-target kinase inhibitors are used to achieve broad cancer coverage, then multiple signaling pathways are inhibited, but therapeutic efficacy decreases due to nonspecific inhibition
Solution Approach 1:
The patent extracts the specific inhibitory mechanism against RET kinase from the nonspecific multi-target inhibition. By designing compounds that form specific hydrogen bonds with key residues (Met804, Thr805, Glu783) in the RET kinase binding pocket and utilizing the unique structural features of RET (such as the activation loop and hydrophobic pocket), the invention achieves selective RET inhibition that reliably targets RET-driven cancer pathways without the nonspecific effects that reduce therapeutic efficacy.
Solution Approach 2:
The patent optimizes local molecular properties through specific substituent selections (R1 for hydrophobic interactions, R2 for hydrogen bonding, R3 and R4 for steric and electronic effects) that create high selectivity for RET kinase. This localized optimization of binding interactions ensures reliable and potent inhibition of RET-driven signaling pathways while avoiding off-target effects on VEGFR2 and other kinases, thereby improving therapeutic efficacy through specific rather than nonspecific inhibition.
Data Source
AI summary
The present invention relates to a pyrazolo[1,5-a]pyridine derivative, a preparation method therefor, and a composition and a use thereof. Specifically, the present invention relates to the compound of formula (I) and the use thereof for the treatment and/or prevention of wild type, gene-fusion type (including but not limited to KIF5B, CCDC6 and NCOA4) and mutant type (including but not limited to V804, G810 and M918) RET kinases-related diseases, including diseases or conditions mediated by RET kinase.